Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.3 (market cap $4.02B), while State Street SPDR S&P Biotech ETF trades at $147.31 (market cap $10.05B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.5× Edgewise Therapeutics Inc. Common Stock's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (10,367,649 versus 1,446,128). Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| EWTX | XBI | |
|---|---|---|
Market Cap | $4.02B | $10.05B |
Volume | 1,446,128 | 10,367,649 |
Sector | Health | Broad Market / Factor |
52-Week High | $48.35 | $169.55 |
52-Week Low | $14.89 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $3.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $146.8, down 3.04% today amid a bearish technical signal. The ETF's modified equal-weight structure provides exposure to over 150 biotech names, benefiting from M&A activity and positive clinical catalysts. Recent news highlights a 76% prior-year rally and optimism around cancer vaccine breakthroughs from Merck and Moderna. However, the ETF carries higher volatility and expense ratios compared to broader healthcare funds.
Outlook remains mixed with technical indicators bearish but fundamental catalysts present. Investment opportunity lies in targeted biotech exposure and sector innovation, though risks include high volatility, regulatory uncertainty, and reliance on clinical trial successes. Analyst consensus is neutral with 100% hold rating, suggesting cautious optimism amid recent price declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
